Long non‑coding RNA cyclin‑dependent kinase inhibitor 2B antisense ribonucleic acid 1 is associated with in‑stent restenosis and promotes human carotid artery smooth muscle cell proliferation and migration by sponging miR‑143‑3p

Ma,Huanhuan; Dong,Aiqin

doi:10.3892/etm.2021.9665

Long non‑coding RNA cyclin‑dependent kinase inhibitor 2B antisense ribonucleic acid 1 is associated with in‑stent restenosis and promotes human carotid artery smooth muscle cell proliferation and migration by sponging miR‑143‑3p

Authors:
- Huanhuan Ma
- Aiqin Dong
View Affiliations

Affiliations: Department of Neurology, Cangzhou Central Hospital, Cangzhou, Hebei 061000, P.R. China
Published online on: January 21, 2021 https://doi.org/10.3892/etm.2021.9665
Article Number: 234
Copyright: © Ma et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Carotid angioplasty and stenting (CAS) is an efficient therapeutic approach for carotid stenosis. However, in‑stent restenosis (ISR) frequently occurs and seriously affects the therapeutic efficacy of CAS. Certain non‑coding (nc)RNAs serve potential roles in ISR development and progression. Thus, the goals of the present study were to investigate novel biomarkers for ISR development and to further uncover the mechanisms underlying the progression of ISR. The expression of long ncRNA cyclin‑dependent kinase inhibitor (CDKN)2B‑antisense 1 (AS1) and microRNA (miR)‑143‑3p in patients with ISR and human carotid artery smooth muscle cells (hHCtASMCs) was analyzed using reverse transcription‑quantitative PCR. A luciferase reporter assay was performed to examine the interaction between CDKN2B‑AS1 and miR‑143‑3p. The effects of the CDKN2B/miR‑143‑3p axis on hHCtASMC proliferation and migration were assessed using Cell Counting Kit‑8 and Transwell assays. The results indicated that serum CDKN2B‑AS1 was increased and miR‑143‑3p was decreased in patients with ISR as compared with that in patients with no ISR (all P<0.001). CDKN2B‑AS1 and miR‑143‑3p were identified as risk factors for ISR onset (all P<0.05) and knockdown of CDKN2B‑AS1 in hHCtASMCs led to inhibited cell proliferation and migration. Furthermore, the luciferase reporter assay and expression analysis indicated that miR‑143‑3p is a target of CDKN2B‑AS1 and may mediate the effects of CDKN2B‑AS1 on hHCtASMC proliferation and migration. In conclusion, dysregulation of CDKN2B‑AS1 and miR‑143‑3p may represent risk factors for the occurrence of ISR. The in vitro results suggested that the CDKN2B‑AS1/miR‑143‑3p axis may regulate the proliferation and migration of hHCtASMCs, indicating its potential to be developed as a target for preventative measures and therapies for ISR.

View Figures

View References

1	Meschia JF, Klaas JP, Brown RD Jr and Brott TG: Evaluation and management of atherosclerotic carotid stenosis. Mayo Clin Proc. 92:1144–1157. 2017.PubMed/NCBI View Article : Google Scholar
2	Sarikas A, Carrier L, Schenke C, Doll D, Flavigny J, Lindenberg KS, Eschenhagen T and Zolk O: Impairment of the ubiquitin-proteasome system by truncated cardiac myosin binding protein C mutants. Cardiovasc Res. 66:33–44. 2005.PubMed/NCBI View Article : Google Scholar
3	Cheng SF, Brown MM, Simister RJ and Richards T: Contemporary prevalence of carotid stenosis in patients presenting with ischaemic stroke. Br J Surg. 106:872–878. 2019.PubMed/NCBI View Article : Google Scholar
4	De Reuck JL: Pathophysiology of carotid artery disease and related clinical syndromes. Acta Chir Belg. 104:30–34. 2004.PubMed/NCBI View Article : Google Scholar
5	Sherman DG: The carotid artery and stroke. Am Fam Phys. 40 (5 Suppl):41S–44S, 7S-9S. 1989.PubMed/NCBI
6	Fanelli F, Boatta E, Cannavale A, Corona M, Lucatelli P, Wlderk A, Cirelli C and Salvatori FM: Carotid artery stenting: Analysis of a 12-year single-center experience. J Endovasc Ther. 19:749–756. 2012.PubMed/NCBI View Article : Google Scholar
7	AbuRahma AF, Abu-Halimah S, Hass SM, Nanjundappa A, Stone PA, Mousa A, Lough E and Dean LS: Carotid artery stenting outcomes are equivalent to carotid endarterectomy outcomes for patients with post-carotid endarterectomy stenosis. J Vasc Surg. 52:1180–1187. 2010.PubMed/NCBI View Article : Google Scholar
8	Dangas GD, Claessen BE, Caixeta A, Sanidas EA, Mintz GS and Mehran R: In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol. 56:1897–1907. 2010.PubMed/NCBI View Article : Google Scholar
9	Zhang H, Ren KF, Chang H, Wang JL and Ji J: Surface-mediated transfection of a pDNA vector encoding short hairpin RNA to downregulate TGF-β1 expression for the prevention of in-stent restenosis. Biomaterials. 116:95–105. 2017.PubMed/NCBI View Article : Google Scholar
10	Bagyura Z, Kiss L, Berta B, Szilágyi Á, Hirschberg K, Széplaki G, Lux Á, Szelid Z, Soós P and Merkely B: High rate of in-stent restenosis after coronary intervention in carriers of the mutant mannose-binding lectin allele. BMC Cardiovasc Disord. 17(4)2017.PubMed/NCBI View Article : Google Scholar
11	Santulli G: microRNAs distinctively regulate vascular smooth muscle and endothelial cells: Functional implications in angiogenesis, atherosclerosis, and in-stent restenosis. Adv Exp Med Biol. 887:53–77. 2015.PubMed/NCBI View Article : Google Scholar
12	Yuan Y, Liu X, Hao S, He Q and Shen Z: Plasma levels of miR-143 and miR-145 are associated with coronary in-stent restenosis within 1 year of follow-up after drug-eluting stent implantation. Ann Transl Med. 8(756)2020.PubMed/NCBI View Article : Google Scholar
13	He M, Gong Y, Shi J, Pan Z, Zou H, Sun D, Tu X, Tan X, Li J, Li W, et al: Plasma microRNAs as potential noninvasive biomarkers for in-stent restenosis. PLoS One. 9(e112043)2014.PubMed/NCBI View Article : Google Scholar
14	Xu C, Zhai J and Fu Y: LncRNA CDKN2B-AS1 promotes the progression of ovarian cancer by miR-143-3p/SMAD3 axis and predicts a poor prognosis. Neoplasma. 67:782–793. 2020.PubMed/NCBI View Article : Google Scholar
15	Li H, Han S, Sun Q, Yao Y, Li S, Yuan C, Zhang B, Jing B, Wu J, Song Y and Wang H: Long non-coding RNA CDKN2B-AS1 reduces inflammatory response and promotes cholesterol efflux in atherosclerosis by inhibiting ADAM10 expression. Aging (Albany NY). 11:1695–1715. 2019.PubMed/NCBI View Article : Google Scholar
16	Ou M, Li X, Zhao S, Cui S and Tu J: Long non-coding RNA CDKN2B-AS1 contributes to atherosclerotic plaque formation by forming RNA-DNA triplex in the CDKN2B promoter. EBioMedicine. 55(102694)2020.PubMed/NCBI View Article : Google Scholar
17	Huang Y, Xiang B, Liu Y, Wang Y and Kan H: LncRNA CDKN2B-AS1 promotes tumor growth and metastasis of human hepatocellular carcinoma by targeting let-7c-5p/NAP1L1 axis. Cancer Lett. 437:56–66. 2018.PubMed/NCBI View Article : Google Scholar
18	Zhuang H, Cao G, Kou C and Li D: Overexpressed lncRNA CDKN2B-AS1 is an independent prognostic factor for liver cancer and promotes its proliferation. J BUON. 24:1441–1448. 2019.PubMed/NCBI
19	Gasecki AP, Hachinski VC, Mendel T and Barnett HT: Endarterectomy for symptomatic carotid stenosis. Review of the European and North American symptomatic carotid surgery trials. Nebr Med J. 77:121–123. 1992.PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
21	Chen KP, Wang JJ, Wang LJ, Lu J, Qi P, Hu S, Yang XM, Wang HF and Wang DM: Study of correlation between carotid artery tortuosity and atherosclerotic carotid artery stenosis. Zhonghua Wai Ke Za Zhi. 55:608–612. 2017.PubMed/NCBI View Article : Google Scholar : (In Chinese).
22	Puz P, Lasek-Bal A, Urbanek T and Kazibutowska Z: Assessment of cerebral embolism and vascular reserve parameters in patients with carotid artery stenosis. Neurol Neurochir. 50:356–362. 2016.PubMed/NCBI View Article : Google Scholar
23	Wang T, Mei B and Zhang J: Atherosclerotic carotid stenosis and cognitive function. Clin Neurol Neurosurg. 146:64–70. 2016.PubMed/NCBI View Article : Google Scholar
24	Jiang F, Zhang X, Lu YM, Li YG, Zhou X and Wang YS: Elevated level of miR-17 along with decreased levels of TIMP-1 and IL-6 in plasma associated with the risk of in-stent restenosis. Biosci Trends. 13:423–429. 2019.PubMed/NCBI View Article : Google Scholar
25	O'Sullivan JF, Neylon A, Fahy EF, Yang P, McGorrian C and Blake GJ: MiR-93-5p is a novel predictor of coronary in-stent restenosis. Heart Asia. 11(e011134)2019.PubMed/NCBI View Article : Google Scholar
26	Wang F, Su X, Liu C, Wu M and Li B: Prognostic value of plasma long noncoding RNA ANRIL for in-stent restenosis. Med Sci Monit. 23:4733–4739. 2017.PubMed/NCBI View Article : Google Scholar
27	Zhu L, Zhang Q, Li S, Jiang S, Cui J and Dang G: Interference of the long noncoding RNA CDKN2B-AS1 upregulates miR-181a-5p/TGFβI axis to restrain the metastasis and promote apoptosis and senescence of cervical cancer cells. Cancer Med. 8:1721–1730. 2019.PubMed/NCBI View Article : Google Scholar
28	Frismantiene A, Philippova M, Erne P and Resink TJ: Smooth muscle cell-driven vascular diseases and molecular mechanisms of VSMC plasticity. Cell Signal. 52:48–64. 2018.PubMed/NCBI View Article : Google Scholar
29	He Y, Zou P, Lu Y, Jia D, Li X, Yang H, Tang L, Zhu Z, Tu T, Tai S, et al: Osteoprotegerin promotes intimal hyperplasia and contributes to in-stent restenosis: Role of an αVβ3/FAK dependent YAP pathway. J Mol Cell Cardiol. 139:1–13. 2020.PubMed/NCBI View Article : Google Scholar
30	Shi L, Tian C, Sun L, Cao F and Meng Z: The lncRNA TUG1/miR-145-5p/FGF10 regulates proliferation and migration in VSMCs of hypertension. Biochem Biophys Res Commun. 501:688–695. 2018.PubMed/NCBI View Article : Google Scholar
31	Tang R, Mei X, Wang YC, Cui XB, Zhang G, Li W and Chen SY: LncRNA GAS5 regulates vascular smooth muscle cell cycle arrest and apoptosis via p53 pathway. Biochim Biophys Acta Mol Basis Dis. 1865:2516–2525. 2019.PubMed/NCBI View Article : Google Scholar